| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6074268 | Journal of Dermatological Science | 2014 | 6 Pages |
Abstract
Clinical experience from more than 1250 injections in 51 patients over four years indicates that omalizumab is a rapidly acting, highly effective and safe drug in CSU and CindU patients. Our observations in a real life clinical setting support the recommendation of current EAACI/GA2LEN/EDF/WAO guideline for the management of urticaria to use omalizumab to treat urticaria patients.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Martin Metz, Tatevik Ohanyan, Martin K. Church, Marcus Maurer,